Literature DB >> 4052628

beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway.

I Schousboe.   

Abstract

The general hypothesis for the biological function of beta 2-glycoprotein I is that it neutralizes all negatively charged macromolecules that might enter the bloodstream and diminishes unwanted activation of the blood coagulation. In the present study we report that beta 2-glycoprotein I inhibits the activation of the contact phase system of the intrinsic pathway of blood coagulation. Activation was accomplished by an ellagic acid-phospholipid suspension (Cephotest) and measured by the appearance of amidolytic activity using the chromogenic substrate H-D-Pro-Phe-Arg-p-nitroanilide (S-2302). This inhibitory effect of beta 2-glycoprotein I was observed both when Cephotest was preincubated with beta 2-glycoprotein I and when the amount of beta 2-glycoprotein I in plasma was increased by addition of beta 2-glycoprotein I to either normal or beta 2-glycoprotein I-deficient plasma. The inhibitory effect of beta 2-glycoprotein I on the contact phase activation could be one of the physiological functions of this protein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4052628

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

Review 1.  Testing for and clinical significance of anticardiolipin antibodies.

Authors:  S W Reddel; S A Krilis
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids.

Authors:  T A Brighton; Y P Dai; P J Hogg; C N Chesterman
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

3.  Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay.

Authors:  Yan Ye; Zhigang Hu; Jie Liu; Guoqian Chen; Yaohong Zhou; Lei Yu
Journal:  Clin Rheumatol       Date:  2012-06-10       Impact factor: 2.980

4.  Val/Leu247 and Trp/Ser316 polymorphisms in beta 2 glycoprotein I and their association with thrombosis in unselected Chilean patients.

Authors:  Iván Palomo; Jaime Pereira; Marcelo Alarcón; Marcela Vásquez; Carmen Pinochet; Fernando Poblete; Evelyn Mendez; Jeannette Sandoval; Rolando Vidal; Silvia Pierangeli
Journal:  Clin Rheumatol       Date:  2006-05-25       Impact factor: 2.980

5.  Thrombophilia Caused by Beta2-Glycoprotein I Deficiency: In Vitro Study of a Rare Mutation in APOH Gene.

Authors:  Xiao-Ping Zhang; Wei Zeng; Hui Liu; Liang Tang; Qing-Yun Wang; Zhi-Peng Cheng; Ying-Ying Wu; Bei Hu; Wei Shi; Yu Hu
Journal:  Curr Med Sci       Date:  2018-04-30

6.  beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin.

Authors:  S K Moestrup; I Schousboe; C Jacobsen; J R Leheste; E I Christensen; T E Willnow
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

7.  Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis.

Authors:  Taro Sakai; Krishnakumar Balasubramanian; Sourindra Maiti; Jyotsna B Halder; Alan J Schroit
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

Review 8.  The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

Authors:  E N Harris
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

9.  Heterogeneity of the apolipoprotein H*3 allele and its role in affecting the binding of apolipoprotein H (beta 2-glycoprotein I) to anionic phospholipids.

Authors:  M I Kamboh; D R Wagenknecht; J A McIntyre
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

10.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.